Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?

Therapies 58

Therapies RNA Protein Expression DNA 58

Drug Discovery World

FEBRUARY 28, 2023

The half-life of proteins expressed through the mRNA technology is also much longer than those of direct protein delivery, which suggests that it could be more effective as a treatment strategy for rare diseases. Therefore, the risk for off-target insertional mutagenesis is greatly reduced.

Disease 130

Disease Treatment Vaccine DNA 130

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It Field also covered the capabilities and strategies that enable acceleration of Fc-fusion, Fab fragment and bispecific antibodies through pre-clinical development.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Alta Sciences

APRIL 17, 2024

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

MARCH 20, 2023

As the number of patients treated with gene therapy around the world continues to grow, our goal is that more patients, and even new SMA patient populations, will be able to experience the transformative impact of this treatment,” said Sitra Tauscher-Wisniewski, MD, Vice President Clinical Development & Analytics, Novartis Gene Therapies.

Licensing 40

Licensing Licensing Clinical Trials Therapies 40

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, there will be two luncheon presentations: Joseph Rucker, PhD, Vice President, Research & Development, Integral Molecular, on: ‘A humanised chicken antibody platform that delivers diverse and developable therapeutic candidates’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147